Trial reportDrugs2009
Prucalopride.
Trial report in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression.Psychological medicine · 2026Trial
- 5-HTBiological psychiatry. Cognitive neuroscience and neuroimaging · 2023Trial
- Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women.Drugs in R&D · 2013Trial
- Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study.Neurogastroenterology and motility · 2012Trial
- Prokinetic drugs that stimulate 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Review
- Pharmacokinetics and bioequivalence assessment of two prucalopride formulations in healthy Chinese women: a randomized, open-label, two-period, two-sequence, self-crossover study.Frontiers in pharmacology · 2025Article
- Development of novel transition metal-catalyzed synthetic approaches for the synthesis of a dihydrobenzofuran nucleus: a review.RSC advances · 2024Review
- Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics.Journal of personalized medicine · 2022Review
- The Effect of the 5-HTFrontiers in psychiatry · 2022Article
- Déjà-vu? Neural and behavioural effects of the 5-HTTranslational psychiatry · 2021Article
- Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.Current gastroenterology reports · 2020Review
- Prucalopride inhibits the glioma cells proliferation and induces autophagy via AKT-mTOR pathway.BMC neurology · 2018Article
- Expert consensus on the assessment and treatment of chronic constipation in the elderly.Aging medicine (Milton (N.S.W)) · 2018Article
- QT-interval prolongation due to medication found in the preoperative evaluation.Journal of dental anesthesia and pain medicine · 2017Article
- Patient considerations in the management of chronic constipation: focus on prucalopride.Patient preference and adherence · 2016Review
- Factors predictive of treatment-emergent adverse events of prucalopride: an integrated analysis of four randomized, double-blind, placebo-controlled trials.Gut and liver · 2015Article
- Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.Techniques in coloproctology · 2014Review
- Understanding and treating refractory constipation.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
- New and future drug development for gastroesophageal reflux disease.Journal of neurogastroenterology and motility · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prucalopride, a first-in-class dihydrobenzofuran-carboxamide derivative, is a potent, selective and specific serotonin 5-HT(4) receptor agonist with enterokinetic properties. Over a 12-week treatment period, prucalopride 2 and 4 mg once daily significantly improved bowel habit assessments (based on patient diary data) relative to placebo in three large, randomized, double-blind, multicentre trials in patients (aged 17-95 years) with severe chronic constipation, the majority of whom were women who experienced inadequate relief with previous therapies. There was no additional benefit with the 4 mg/day over the 2 mg/day dosage of prucalopride. Patient assessments of constipation symptoms and severity, treatment efficacy, satisfaction with bowel habit and treatment, and health-related quality of life were also significantly improved with prucalopride compared with placebo. The improvement in patient satisfaction with bowel habit and treatment was maintained for up to 24 months in open-label, multicentre, long-term follow-up studies. Prucalopride therapy was generally well tolerated; most adverse events in the 12-week studies were transient and of mild to moderate severity. In terms of cardiovascular tolerability, the incidence of QT interval prolongation with prucalopride at dosages of 2 and 4 mg/day was low and similar to that with placebo. Moreover, prucalopride at dosages up to 20 mg/day (10-fold higher than the recommended therapeutic dosage) had no clinically relevant effects on cardiovascular parameters in healthy volunteers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.